HIV Post-Exposure Prophylaxis (PEP) Drugs - Global Top Players Market Share and Ranking 2026- YH Research

Home > Reports >Pharma & Healthcare > HIV Post-Exposure Prophylaxis (PEP) Drugs - Global Top Players Market Share and Ranking 2026

HIV Post-Exposure Prophylaxis (PEP) Drugs - Global Top Players Market Share and Ranking 2026

Publication Date: 2026-09-10
Report Id: 3155779
Industry: Pharma & Healthcare
Report Page: 122
Chart: 122

PDF Download

Publication Date: 2026-09-10
Report Id: 3155779
Industry: Pharma & Healthcare
Report Page: 122
Chart: 122

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 HIV Post-Exposure Prophylaxis (PEP) Drugs Definition
1.2 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size and Forecast
1.2.1 By Consumption Value, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size, 2021-2032
1.2.2 By Sales Quantity, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size, 2021-2032
1.2.3 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Average Selling Price (ASP), 2021-2032
1.3 Japan HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size and Forecast
1.3.1 By Consumption Value, Japan HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size, 2021-2032
1.3.2 By Sales Quantity, Japan HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size, 2021-2032
1.3.3 Japan HIV Post-Exposure Prophylaxis (PEP) Drugs Average Selling Price (ASP), 2021-2032
1.4 Share of Japan HIV Post-Exposure Prophylaxis (PEP) Drugs Market with Respect to the Global Market
1.4.1 By Consumption Value, Japan HIV Post-Exposure Prophylaxis (PEP) Drugs Market Share in Global, 2021-2032
1.4.2 By Sales Quantity, Japan HIV Post-Exposure Prophylaxis (PEP) Drugs Market Share in Global, 2021-2032
1.4.3 HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size: Japan VS Global, 2021-2032
1.5 HIV Post-Exposure Prophylaxis (PEP) Drugs Market Dynamics
1.5.1 HIV Post-Exposure Prophylaxis (PEP) Drugs Market Drivers
1.5.2 HIV Post-Exposure Prophylaxis (PEP) Drugs Market Restraints
1.5.3 HIV Post-Exposure Prophylaxis (PEP) Drugs Industry Trends
1.5.4 HIV Post-Exposure Prophylaxis (PEP) Drugs Industry Policy

2 Global Leading Manufacturers and Market Share
2.1 By Revenue of HIV Post-Exposure Prophylaxis (PEP) Drugs, Global Market Share by Company, 2021-2026
2.2 By Sales Quantity of HIV Post-Exposure Prophylaxis (PEP) Drugs, Global Market Share by Company, 2021-2026
2.3 HIV Post-Exposure Prophylaxis (PEP) Drugs Average Selling Price (ASP) by Company, 2021-2026
2.4 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.5 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Concentration Ratio
2.6 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Mergers & Acquisitions, Expansion Plans
2.7 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Manufacturers Product Type
2.8 Head Office and HIV Post-Exposure Prophylaxis (PEP) Drugs Production Site of Key Manufacturer
2.9 HIV Post-Exposure Prophylaxis (PEP) Drugs Capacity of Major Manufacturers and Future Plan

3 Japan Leading Manufacturers and Market Share
3.1 By Revenue of HIV Post-Exposure Prophylaxis (PEP) Drugs, Japan Market Share by Company, 2021-2026
3.2 By Sales Quantity of HIV Post-Exposure Prophylaxis (PEP) Drugs, Japan Market Share by Company, 2021-2026
3.3 Japan HIV Post-Exposure Prophylaxis (PEP) Drugs HIV Post-Exposure Prophylaxis (PEP) Drugs Participants, Market Position (Tier 1, Tier 2, and Tier 3)

4 Global Producing Regions
4.1 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Capacity, Output and Capacity Utilization, 2021-2032
4.2 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Capacity by Region
4.3 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Production & Forecast by Region, 2021 VS 2025 VS 2032
4.4 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Production by Region, 2021-2032
4.5 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Production Market Share & Forecast by Region, 2021-2032

5 Industry Chain Analysis
5.1 HIV Post-Exposure Prophylaxis (PEP) Drugs Industry Chain
5.2 HIV Post-Exposure Prophylaxis (PEP) Drugs Upstream Analysis
5.2.1 HIV Post-Exposure Prophylaxis (PEP) Drugs Core Raw Materials
5.2.2 Main Manufacturers of HIV Post-Exposure Prophylaxis (PEP) Drugs Core Raw Materials
5.3 Midstream Analysis
5.4 Downstream Analysis
5.5 HIV Post-Exposure Prophylaxis (PEP) Drugs Production Mode
5.6 HIV Post-Exposure Prophylaxis (PEP) Drugs Procurement Model
5.7 HIV Post-Exposure Prophylaxis (PEP) Drugs Industry Sales Model and Sales Channels
5.7.1 HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Model
5.7.2 HIV Post-Exposure Prophylaxis (PEP) Drugs Typical Distributors

6 Sights HIV Post-Exposure Prophylaxis (PEP) Drugs Market Classification
6.1 HIV Post-Exposure Prophylaxis (PEP) Drugs Classification by Type
6.1.1 Single Active Ingredient Products
6.1.2 Two Active Ingredient Fixed Dose Combinations
6.1.3 Three Active Ingredient Fixed Dose Combinations
6.1.4 Four Active Ingredient Fixed Dose Combinations
6.1.5 Other
6.1.6 by Type, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Consumption Value, 2021-2032
6.1.7 by Type, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, 2021-2032
6.1.8 by Type, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Average Selling Price (ASP), 2021-2032
6.2 HIV Post-Exposure Prophylaxis (PEP) Drugs Classification by NRTI Backbone Type
6.2.1 Tenofovir Disoproxil Fumarate Based
6.2.2 Tenofovir Alafenamide Based
6.2.3 Abacavir Based
6.2.4 Zidovudine Based
6.2.5 Other
6.2.6 by NRTI Backbone Type, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Consumption Value, 2021-2032
6.2.7 by NRTI Backbone Type, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, 2021-2032
6.2.8 by NRTI Backbone Type, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Average Selling Price (ASP), 2021-2032

7 Sights by Application
7.1 HIV Post-Exposure Prophylaxis (PEP) Drugs Segment by Application
7.1.1 Occupational Exposure PEP
7.1.2 Consensual Sexual Exposure PEP
7.1.3 Sexual Assault Exposure PEP
7.1.4 Injection Drug Use Exposure PEP
7.1.5 Other
7.2 by Application, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Consumption Value & CAGR, 2021 VS 2025 VS 2032
7.3 by Application, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Consumption Value, 2021-2032
7.4 by Application, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, 2021-2032
7.5 by Application, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Price, 2021-2032

8 Sales Sights by Region
8.1 By Region, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Consumption Value, 2021 VS 2025 VS 2032
8.2 By Region, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Consumption Value, 2021-2032
8.3 By Region, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, 2021-2032
8.4 North America
8.4.1 North America HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size & Forecasts, 2021-2032
8.4.2 By Country, North America HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size Market Share
8.5 Europe
8.5.1 Europe HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size & Forecasts, 2021-2032
8.5.2 By Country, Europe HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size Market Share
8.6 Asia Pacific
8.6.1 Asia Pacific HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size & Forecasts, 2021-2032
8.6.2 By Country/Region, Asia Pacific HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size Market Share
8.7 South America
8.7.1 South America HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size & Forecasts, 2021-2032
8.7.2 By Country, South America HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size Market Share
8.8 Middle East & Africa

9 Sales Sights by Country Level
9.1 By Country, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size & CAGR, 2021 VS 2025 VS 2032
9.2 By Country, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Consumption Value, 2021-2032
9.3 By Country, Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, 2021-2032
9.4 United States
9.4.1 United States HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size, 2021-2032
9.4.2 by Type, United States HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity Market Share, 2025 VS 2032
9.4.3 by Application, United States HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity Market Share, 2025 VS 2032
9.5 Europe
9.5.1 Europe HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size, 2021-2032
9.5.2 by Type, Europe HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity Market Share, 2025 VS 2032
9.5.3 by Application, Europe HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity Market Share, 2025 VS 2032
9.6 China
9.6.1 China HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size, 2021-2032
9.6.2 by Type, China HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity Market Share, 2025 VS 2032
9.6.3 by Application, China HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity Market Share, 2025 VS 2032
9.7 Japan
9.7.1 Japan HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size, 2021-2032
9.7.2 by Type, Japan HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity Market Share, 2025 VS 2032
9.7.3 by Application, Japan HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity Market Share, 2025 VS 2032
9.8 South Korea
9.8.1 South Korea HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size, 2021-2032
9.8.2 by Type, South Korea HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity Market Share, 2025 VS 2032
9.8.3 by Application, South Korea HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity Market Share, 2025 VS 2032
9.9 Southeast Asia
9.9.1 Southeast Asia HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size, 2021-2032
9.9.2 by Type, Southeast Asia HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity Market Share, 2025 VS 2032
9.9.3 by Application, Southeast Asia HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity Market Share, 2025 VS 2032
9.10 India
9.10.1 India HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size, 2021-2032
9.10.2 by Type, India HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity Market Share, 2025 VS 2032
9.10.3 by Application, India HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity Market Share, 2025 VS 2032
9.11 Middle East & Africa
9.11.1 Middle East & Africa HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size, 2021-2032
9.11.2 by Type, Middle East & Africa HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity Market Share, 2025 VS 2032
9.11.3 by Application, Middle East & Africa HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity Market Share, 2025 VS 2032

10 Manufacturers Profile
10.1 Gilead Sciences, Inc.
10.1.1 Gilead Sciences, Inc. Company Information, Head Office, Market Area, and Industry Position
10.1.2 Gilead Sciences, Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.1.3 Gilead Sciences, Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.1.4 Gilead Sciences, Inc. Company Profile and Main Business
10.1.5 Gilead Sciences, Inc. Recent Developments
10.2 ViiV Healthcare
10.2.1 ViiV Healthcare Company Information, Head Office, Market Area, and Industry Position
10.2.2 ViiV Healthcare HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.2.3 ViiV Healthcare HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.2.4 ViiV Healthcare Company Profile and Main Business
10.2.5 ViiV Healthcare Recent Developments
10.3 Merck & Co., Inc.
10.3.1 Merck & Co., Inc. Company Information, Head Office, Market Area, and Industry Position
10.3.2 Merck & Co., Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.3.3 Merck & Co., Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.3.4 Merck & Co., Inc. Company Profile and Main Business
10.3.5 Merck & Co., Inc. Recent Developments
10.4 Johnson & Johnson
10.4.1 Johnson & Johnson Company Information, Head Office, Market Area, and Industry Position
10.4.2 Johnson & Johnson HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.4.3 Johnson & Johnson HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.4.4 Johnson & Johnson Company Profile and Main Business
10.4.5 Johnson & Johnson Recent Developments
10.5 Viatris Inc.
10.5.1 Viatris Inc. Company Information, Head Office, Market Area, and Industry Position
10.5.2 Viatris Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.5.3 Viatris Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.5.4 Viatris Inc. Company Profile and Main Business
10.5.5 Viatris Inc. Recent Developments
10.6 Cipla Limited
10.6.1 Cipla Limited Company Information, Head Office, Market Area, and Industry Position
10.6.2 Cipla Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.6.3 Cipla Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.6.4 Cipla Limited Company Profile and Main Business
10.6.5 Cipla Limited Recent Developments
10.7 Aurobindo Pharma Limited
10.7.1 Aurobindo Pharma Limited Company Information, Head Office, Market Area, and Industry Position
10.7.2 Aurobindo Pharma Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.7.3 Aurobindo Pharma Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.7.4 Aurobindo Pharma Limited Company Profile and Main Business
10.7.5 Aurobindo Pharma Limited Recent Developments
10.8 Hetero Labs Limited
10.8.1 Hetero Labs Limited Company Information, Head Office, Market Area, and Industry Position
10.8.2 Hetero Labs Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.8.3 Hetero Labs Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.8.4 Hetero Labs Limited Company Profile and Main Business
10.8.5 Hetero Labs Limited Recent Developments
10.9 Macleods Pharmaceuticals Limited
10.9.1 Macleods Pharmaceuticals Limited Company Information, Head Office, Market Area, and Industry Position
10.9.2 Macleods Pharmaceuticals Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.9.3 Macleods Pharmaceuticals Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.9.4 Macleods Pharmaceuticals Limited Company Profile and Main Business
10.9.5 Macleods Pharmaceuticals Limited Recent Developments
10.10 Laurus Labs Limited
10.10.1 Laurus Labs Limited Company Information, Head Office, Market Area, and Industry Position
10.10.2 Laurus Labs Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.10.3 Laurus Labs Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.10.4 Laurus Labs Limited Company Profile and Main Business
10.10.5 Laurus Labs Limited Recent Developments
10.11 Emcure Pharmaceuticals Limited
10.11.1 Emcure Pharmaceuticals Limited Company Information, Head Office, Market Area, and Industry Position
10.11.2 Emcure Pharmaceuticals Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.11.3 Emcure Pharmaceuticals Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.11.4 Emcure Pharmaceuticals Limited Company Profile and Main Business
10.11.5 Emcure Pharmaceuticals Limited Recent Developments
10.12 Aspen Pharmacare Holdings Limited
10.12.1 Aspen Pharmacare Holdings Limited Company Information, Head Office, Market Area, and Industry Position
10.12.2 Aspen Pharmacare Holdings Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.12.3 Aspen Pharmacare Holdings Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.12.4 Aspen Pharmacare Holdings Limited Company Profile and Main Business
10.12.5 Aspen Pharmacare Holdings Limited Recent Developments
10.13 Strides Pharma Science Limited
10.13.1 Strides Pharma Science Limited Company Information, Head Office, Market Area, and Industry Position
10.13.2 Strides Pharma Science Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.13.3 Strides Pharma Science Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.13.4 Strides Pharma Science Limited Company Profile and Main Business
10.13.5 Strides Pharma Science Limited Recent Developments
10.14 Lupin Limited
10.14.1 Lupin Limited Company Information, Head Office, Market Area, and Industry Position
10.14.2 Lupin Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.14.3 Lupin Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.14.4 Lupin Limited Company Profile and Main Business
10.14.5 Lupin Limited Recent Developments
10.15 Micro Labs Limited
10.15.1 Micro Labs Limited Company Information, Head Office, Market Area, and Industry Position
10.15.2 Micro Labs Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.15.3 Micro Labs Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.15.4 Micro Labs Limited Company Profile and Main Business
10.15.5 Micro Labs Limited Recent Developments
10.16 Sun Pharmaceutical Industries Limited
10.16.1 Sun Pharmaceutical Industries Limited Company Information, Head Office, Market Area, and Industry Position
10.16.2 Sun Pharmaceutical Industries Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.16.3 Sun Pharmaceutical Industries Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.16.4 Sun Pharmaceutical Industries Limited Company Profile and Main Business
10.16.5 Sun Pharmaceutical Industries Limited Recent Developments
10.17 Celltrion Inc.
10.17.1 Celltrion Inc. Company Information, Head Office, Market Area, and Industry Position
10.17.2 Celltrion Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.17.3 Celltrion Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.17.4 Celltrion Inc. Company Profile and Main Business
10.17.5 Celltrion Inc. Recent Developments
10.18 Shanghai Desano Bio-Pharmaceutical Co., Ltd.
10.18.1 Shanghai Desano Bio-Pharmaceutical Co., Ltd. Company Information, Head Office, Market Area, and Industry Position
10.18.2 Shanghai Desano Bio-Pharmaceutical Co., Ltd. HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.18.3 Shanghai Desano Bio-Pharmaceutical Co., Ltd. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.18.4 Shanghai Desano Bio-Pharmaceutical Co., Ltd. Company Profile and Main Business
10.18.5 Shanghai Desano Bio-Pharmaceutical Co., Ltd. Recent Developments
10.19 Zhejiang Huahai Pharmaceutical Co., Ltd.
10.19.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information, Head Office, Market Area, and Industry Position
10.19.2 Zhejiang Huahai Pharmaceutical Co., Ltd. HIV Post-Exposure Prophylaxis (PEP) Drugs Models, Specifications, and Application
10.19.3 Zhejiang Huahai Pharmaceutical Co., Ltd. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.19.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Company Profile and Main Business
10.19.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments

11 Conclusion

12 Appendix
12.1 Research Methodology
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Market Estimation Model
12.4 Disclaimer

According to YH Research, the global market for HIV Post-Exposure Prophylaxis (PEP) Drugs should grow from US$ 197 million in 2025 to US$ 307 million by 2032, with a CAGR of 6.5% for the period of 2026-2032.

HIV Post-Exposure Prophylaxis (PEP) Drugs refer to antiretroviral medicines administered after a potential HIV exposure to reduce the probability of establishing infection. The market primarily covers oral antiretroviral formulations used in standard PEP courses, including single-active-ingredient products and two-, three- and four-active-ingredient fixed-dose combinations. Current mainstream regimens are centered on integrase inhibitor-based three-drug therapy, with bictegravir or dolutegravir combined with a tenofovir-based nucleoside reverse transcriptase inhibitor backbone, while boosted protease inhibitor-based regimens remain alternatives for selected patients. Treatment is normally initiated as soon as possible following substantial occupational or nonoccupational exposure, ideally within 24 hours and no later than 72 hours, with a standard treatment duration of 28 days. The study focuses on commercial finished-dose antiretroviral products actually used for HIV PEP across occupational exposure, consensual sexual exposure, sexual assault exposure, injection drug use exposure and other nonoccupational blood or body-fluid exposure scenarios, covering branded originator products, licensed generics and other commercially supplied generic formulations.

HIV Post-Exposure Prophylaxis (PEP) Drugs

According to YH Research, the global market for HIV Post-Exposure Prophylaxis (PEP) Drugs should grow from US$ 197 million in 2025 to US$ 307 million by 2032, with a CAGR of 6.5% for the period of 2026-2032.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

Key Findings
Global HIV PEP drug consumption is estimated at approximately 43.7 million tablets in 2025 and 46.2 million tablets in 2026
Global PEP utilization corresponds to approximately 1.08 million treatment courses in 2025 and 1.16 million courses in 2026
North America and Europe together account for approximately 82% of 2026 market value, reflecting substantially higher realized drug prices
Integrase inhibitor-based three-drug regimens and fixed-dose combinations have become the mainstream product architecture for HIV PEP
Large-scale generic ARV procurement provides ample manufacturing capacity, while market value remains highly differentiated by region and pricing system
Market Trends
HIV Post-Exposure Prophylaxis (PEP) Drugs are moving toward simpler, better tolerated and lower-pill-burden regimens. Newer clinical recommendations favor second-generation integrase inhibitors, particularly bictegravir and dolutegravir, combined with two NRTIs, supporting increased use of three-active-ingredient fixed-dose combinations and simplified once-daily treatment. Bictegravir, emtricitabine and tenofovir alafenamide can provide a complete single-tablet regimen, while dolutegravir combined with TDF or TAF and FTC or 3TC remains a widely applicable architecture. The product mix is therefore gradually shifting away from older high-pill-burden combinations toward integrated fixed-dose products that improve adherence during the 28-day course. At the delivery level, PEP is also moving beyond specialist infectious-disease departments toward emergency care, sexual health services, occupational health programs and community-based access models, reflecting the critical importance of initiating treatment rapidly after exposure. Pediatric dispersible tablets, chewable tablets, oral suspensions and solutions remain a smaller but strategically important part of the product portfolio.

Market Dynamics
Drivers
Growth of HIV Post-Exposure Prophylaxis (PEP) Drugs is supported by broader recognition of PEP as an emergency HIV prevention intervention, improved awareness among exposed populations and healthcare professionals, and continued integration of PEP into national HIV prevention systems. Occupational sharps injuries, sexual exposure, sexual assault and injection-related exposure create recurring clinical demand, while policies emphasizing initiation within 72 hours increase the need for readily available starter packs and full 28-day courses. Expansion of emergency, sexual-health and community delivery networks further improves treatment accessibility.

Restraints
The market remains constrained by large differences in affordability and access between countries. High-income markets may use branded or higher-value newer-generation formulations, whereas public procurement programs in lower-income markets purchase highly commoditized generic ARVs at substantially lower prices. The Global Fund's 2026 reference price for a 30-tablet pack of dolutegravir, lamivudine and tenofovir is only US$2.80, illustrating the intense price compression in large-volume procurement markets. In addition, expanding PrEP use among populations with repeated HIV exposure can reduce recurring PEP demand, while stigma, delayed treatment-seeking and failure to present within the recommended 72-hour window continue to limit addressable utilization.

Opportunities
The most significant opportunities lie in improving rapid access and simplifying the treatment pathway. Wider availability through emergency departments, urgent-care centers, sexual health clinics, occupational health services and community-based channels can capture currently unmet PEP demand. Single-tablet three-active-ingredient fixed-dose combinations offer opportunities to reduce pill burden and support completion of the 28-day course, while pediatric formulations provide room for further product expansion. Emerging markets also offer considerable volume potential as national HIV programs strengthen post-exposure prevention services, although commercial models in these markets will remain more dependent on public procurement, licensing and cost-efficient generic manufacturing.

Challenges
The principal challenges are maintaining adherence throughout the full course, ensuring treatment can be initiated rapidly, managing drug interactions and comorbidities, and selecting appropriate alternatives where resistance or contraindications are present. Market measurement is also structurally difficult because most antiretroviral medicines used in PEP are shared with the much larger HIV treatment market rather than manufactured on dedicated PEP production lines. In the United States, current nPEP recommendations use established ARVs for the prevention setting rather than a separate portfolio of PEP-specific approved products. As a result, manufacturers and market participants must distinguish actual PEP consumption from treatment and PrEP volumes when assessing demand, inventory and revenue.

Industry Chain Analysis
The upstream segment of the HIV Post-Exposure Prophylaxis (PEP) Drugs industry consists primarily of pharmaceutical intermediates, antiretroviral APIs, excipients and pharmaceutical packaging materials. Major active ingredients include dolutegravir, bictegravir, tenofovir disoproxil fumarate, tenofovir alafenamide, emtricitabine, lamivudine, raltegravir and darunavir. Midstream activities comprise API synthesis, formulation development, fixed-dose combination development, regulatory filing, commercial-scale tablet manufacturing, pediatric formulation production, packaging and quality assurance. Vertically integrated generic manufacturers have a structural advantage in international procurement because control of both API and finished-dose formulation can improve cost competitiveness and supply reliability; Aurobindo, for example, reports integrated API and finished-dose ARV capabilities and supplies antiretroviral products to more than 125 countries.

Downstream distribution is fragmented by healthcare system. Products reach patients through emergency departments, urgent-care facilities, sexual health clinics, occupational health departments, sexual assault treatment services, public HIV programs, pharmacies and community-based delivery systems. Value creation differs substantially between segments: originator companies capture greater value through proprietary molecules, newer formulations and branded products, while generic manufacturers compete primarily through manufacturing scale, regulatory approvals, licensing, vertical integration and tender pricing. The very low international procurement price of mature ARVs means volume leadership does not necessarily translate into equivalent revenue leadership, making regional product mix and realized price critical determinants of market value.

Segment Insights
By Product Type, three-active-ingredient fixed-dose combinations represent the most strategically important product architecture because they can consolidate a complete three-drug regimen into one tablet. Products containing bictegravir, emtricitabine and tenofovir alafenamide illustrate the high-value single-tablet model, while tenofovir, lamivudine and dolutegravir combinations are especially important in cost-sensitive and large-scale procurement markets. Two-active-ingredient fixed-dose combinations remain important as NRTI backbones used together with a separate integrase inhibitor, while single-active-ingredient products provide flexibility for individualized regimens. Four-active-ingredient fixed-dose combinations are primarily associated with selected boosted protease inhibitor alternatives.

By Regimen Class, integrase inhibitor-based regimens are the mainstream clinical direction, while boosted protease inhibitor-based regimens serve mainly as alternatives. Within the NRTI Backbone Type segmentation, TDF-based products retain strong relevance in cost-sensitive procurement because of extensive generic availability, while TAF-based products are increasingly important in newer-generation regimens in higher-value markets. ABC-based and zidovudine-based products have more specific roles, including selected pediatric or alternative treatment situations. Oral tablets dominate Dosage Form, with dispersible tablets, chewable tablets, oral suspensions and oral solutions addressing pediatric and patients-specific administration requirements.

Downstream Market Opportunities
Application opportunities are centered on specific time-sensitive exposure scenarios rather than broad healthcare settings. Occupational Exposure PEP demand arises from needlestick injuries, contaminated sharps and mucosal blood exposure among healthcare and laboratory personnel. Consensual Sexual Exposure PEP is driven by substantial-risk sexual exposure such as condom failure or unprotected intercourse, while Sexual Assault Exposure PEP requires rapid access through emergency and specialist assault-care pathways. Injection Drug Use Exposure PEP addresses needle and injection-equipment sharing, and Other Nonoccupational Blood and Body Fluid Exposure PEP covers clinically significant blood or infectious-fluid contact with mucous membranes or nonintact skin. Expansion of rapid-access dispensing across these settings creates an opportunity to increase PEP uptake and improve completion rates without changing the underlying 28-day treatment standard.

Regional Insights
North America and Europe form the principal value centers for HIV Post-Exposure Prophylaxis (PEP) Drugs and together account for approximately 82% of the modeled 2026 market value, primarily because branded and newer-generation ARV formulations command significantly higher realized prices than internationally procured generics. Demand is supported by mature emergency-care, sexual-health and occupational-exposure systems. In England alone, sexual health services provided PEP to 8,463 people in 2024, up 4% from 2023, demonstrating continued utilization even in a market with expanding PrEP availability.

Latin America and Sub-Saharan Africa represent much larger volume opportunities relative to their value contribution, reflecting centralized public procurement and low generic ARV prices. Asia Pacific is structurally heterogeneous: Japan, South Korea and other developed markets favor higher-value branded or newer formulations, while China, India and Southeast Asia combine domestic generic manufacturing with expanding public-health access. Future regional growth will therefore depend less on global manufacturing capacity and more on awareness, rapid access, procurement funding and the integration of PEP into emergency and sexual-health services.

Competitive Landscape Analysis
The competitive landscape is characterized by a dual structure combining originator-led innovation with large-scale generic manufacturing. Gilead Sciences, ViiV Healthcare, Merck & Co. and Johnson & Johnson participate through important proprietary HIV molecules and branded formulations used within current or alternative PEP architectures, while Viatris, Cipla, Aurobindo Pharma, Hetero Labs, Macleods Pharmaceuticals, Laurus Labs and Emcure Pharmaceuticals provide significant generic and international-market supply capabilities. Aspen Pharmacare, Strides Pharma Science, Lupin, Micro Labs and Sun Pharmaceutical further broaden the generic manufacturing base, while Celltrion, Shanghai Desano Bio-Pharmaceutical and Zhejiang Huahai Pharmaceutical add regional and manufacturing capacity in Asia. Competitive differentiation is driven less by dedicated PEP manufacturing capacity than by ARV portfolio breadth, access to licensed molecules, regulatory approvals, manufacturing scale, API integration, fixed-dose combination capabilities and access to government or pooled procurement channels. Large generic suppliers have substantial volume advantages, while originator companies retain stronger exposure to higher-value markets and newer-generation formulations.

Report Scope
This report studies and analyses global HIV Post-Exposure Prophylaxis (PEP) Drugs status and future trends, helps the client to determine the HIV Post-Exposure Prophylaxis (PEP) Drugs market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for HIV Post-Exposure Prophylaxis (PEP) Drugs, and provides market size (in K Tablets & US$ million) and Year-over-Year growth, considering 2025 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global HIV Post-Exposure Prophylaxis (PEP) Drugs market size, history data 2021-2025, and forecast data 2026-2032, (US$ million) & (K Tablets)
(2) Global HIV Post-Exposure Prophylaxis (PEP) Drugs sales, revenue, price by company, market share and industry ranking 2021-2026, (US$ million) & (K Tablets)
(3) Japan HIV Post-Exposure Prophylaxis (PEP) Drugs sales, revenue, price by company, market share and industry ranking 2021-2026, (US$ million) & (K Tablets)
(4) Global HIV Post-Exposure Prophylaxis (PEP) Drugs key consuming regions, consumption quantity, consumption value and demand structure
(5) Global HIV Post-Exposure Prophylaxis (PEP) Drugs key producing regions, capacity, production, and year over year growth
(6) HIV Post-Exposure Prophylaxis (PEP) Drugs industry chains, upstream, midstream and downstream
Market Segmentation
Market segment by players, this report covers
    Gilead Sciences, Inc.
    ViiV Healthcare
    Merck & Co., Inc.
    Johnson & Johnson
    Viatris Inc.
    Cipla Limited
    Aurobindo Pharma Limited
    Hetero Labs Limited
    Macleods Pharmaceuticals Limited
    Laurus Labs Limited
    Emcure Pharmaceuticals Limited
    Aspen Pharmacare Holdings Limited
    Strides Pharma Science Limited
    Lupin Limited
    Micro Labs Limited
    Sun Pharmaceutical Industries Limited
    Celltrion Inc.
    Shanghai Desano Bio-Pharmaceutical Co., Ltd.
    Zhejiang Huahai Pharmaceutical Co., Ltd.

Market segment by Type, covers
    Single Active Ingredient Products
    Two Active Ingredient Fixed Dose Combinations
    Three Active Ingredient Fixed Dose Combinations
    Four Active Ingredient Fixed Dose Combinations
    Other

Market segment by NRTI Backbone Type, covers
    Tenofovir Disoproxil Fumarate Based
    Tenofovir Alafenamide Based
    Abacavir Based
    Zidovudine Based
    Other

Market segment by Application, can be divided into
    Occupational Exposure PEP
    Consensual Sexual Exposure PEP
    Sexual Assault Exposure PEP
    Injection Drug Use Exposure PEP
    Other

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Chapter Outline
Chapter 1: to describe HIV Post-Exposure Prophylaxis (PEP) Drugs product scope, global sales quantity, value and average price, Japan sales quantity, value and average price, development opportunities, challenges, trends, and policies
Chapter 2: Global HIV Post-Exposure Prophylaxis (PEP) Drugs market share and ranking of major manufacturers, sales quantity, revenue, average price, 2021-2026
Chapter 3: Japan HIV Post-Exposure Prophylaxis (PEP) Drugs market share and ranking of major manufacturers, sales quantity, revenue, average price, 2021-2026
Chapter 4: Global key producing regions of HIV Post-Exposure Prophylaxis (PEP) Drugs, percent & CAGR, 2021-2032
Chapter 5: HIV Post-Exposure Prophylaxis (PEP) Drugs industry chain, upstream, medium-stream, and downstream
Chapter 6: Segment by Type, sales quantity, average price, consumption value, percent & CAGR, 2021-2032
Chapter 7: Segment by Application, sales quantity, average price, consumption value, percent & CAGR, 2021-2032
Chapter 8: Segment in regional level, sales quantity, average price, consumption value, percent & CAGR, 2021-2032
Chapter 9: Segment in country level, sales quantity, average price, consumption value, percent & CAGR, 2021-2032
Chapter 10: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, sales quantity, average price, revenue, gross margin
Chapter 11: Conclusions